IOncology

At the recent ESMO Asia 2025 Congress, a study by Professor Darren Poon's team at the Hong Kong Comprehensive Oncology Centre was selected, bringing a new precision medicine strategy to patients with advanced prostate cancer. Oncology Frontier- UroStream invited Professor Poon to share his insights on the clinical value and future prospects of liquid biopsy for Chinese patients with androgen receptor ligand binding domain-mutated prostate cancer. #ESMOAsia2025 #prostatecancer #precisionmedicine

Editor’s Note: The 20th Shanghai International Breast Cancer Symposium (SIBCS), organized by the Shanghai Anti-Cancer Association and the Breast Cancer Professional Committee of the China Anti-Cancer Association, was held in…

The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly organized by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was recently held in Shanghai. Under the theme “20 Years of Progress, a Future of Continuity”, the forum brought together leading experts from China and abroad to reflect on two decades of advances in breast cancer diagnosis and treatment in China. During the “Year in Review” session, Professor Feng Jin of the First Hospital of China Medical University delivered a presentation titled “Key Clinical Trial Achievements in Chinese Breast Cancer Research.” Oncology Frontier invited Professor Jin for an in-depth discussion on China’s breakthrough clinical evidence, its global impact, and China’s future developmental directions in breast cancer research.

The 20th Shanghai International Breast Cancer Symposium (SIBCS), jointly hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held from November 13–15, 2025 in Shanghai. During the meeting, Professor Jun-jie Li from Fudan University Shanghai Cancer Center delivered a keynote lecture entitled “Two Decades of Shared Progress: The Journey of China’s Original Innovation and the Rise of SIBCS.” Following the presentation, Oncology Frontier interviewed Professor Li to further discuss the latest advances of China’s original innovative drugs in breast cancer, and to explore how SIBCS enables cross-generational academic exchange and fosters synergistic development between Chinese innovations and the SIBCS platform.

 The 20th Shanghai International Breast Cancer Symposium (SIBCS), hosted by the Shanghai Anti-Cancer Association and the Breast Cancer Committee of the China Anti-Cancer Association, was held on November 13–15, 2025. During the “Hundred Schools of Thought” session, Professor Kun Wang from Guangdong Provincial People’s Hospital delivered an academic presentation titled “Guangdong Experience: Exploring Neoadjuvant Therapy in the New Era.” Following his talk, Oncology Frontier invited Professor Wang to elaborate on his team’s latest clinical progress in breast cancer neoadjuvant therapy, and to share his insights on the evolving role of ADCs and major challenges ahead. 

At the 2025 ESMO Asia Congress, Professor George K.K. Lau, Chairman of Humanity & Health Medical Group, Hong Kong, presented for the first time data from a Chinese population study…

丨 9th East China Breast Cancer Salon** Editor’s Note:  The treatment paradigm for breast cancer brain metastases (BCBM) is undergoing major conceptual shifts. With advances in radiotherapy technology and continuous…

Professor Benlong Yang: Advancing Personalized Breast Reconstruction Through Innovative Techniques and Global Collaboration** Editor’s Note:  The 17th Shanghai Breast Reconstruction Forum was held on November 12–13, 2025, in Shanghai. With…

Editor’s note: Breast cancer has become one of the leading malignancies threatening women’s health. Standardized diagnosis and treatment, together with rigorous quality control, are essential for improving survival outcomes and…

 At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice.